Representative Carol D. Miller (R-West Virginia) recently bought shares of Gilead Sciences, Inc. NASDAQ: GILD. In a filing disclosed on April 11th, the Representative disclosed that they had bought between $1,001 and $15,000 in Gilead Sciences stock on March 10th. The trade occurred in the Representative's "MATT MILLER INVESTMENT MANAGEMENT ACCOUNT" account.
Representative Carol D. Miller also recently made the following trade(s):
- Purchased $1,001 - $15,000 in shares of Aflac NYSE: AFL on 3/10/2025.
- Purchased $1,001 - $15,000 in shares of Hershey NYSE: HSY on 3/10/2025.
- Sold $1,001 - $15,000 in shares of Pfizer NYSE: PFE on 3/10/2025.
- Purchased $1,001 - $15,000 in shares of Lockheed Martin NYSE: LMT on 3/10/2025.
- Purchased $1,001 - $15,000 in shares of PepsiCo NASDAQ: PEP on 3/10/2025.
- Purchased $1,001 - $15,000 in shares of Honeywell International NASDAQ: HON on 3/10/2025.
- Sold $1,001 - $15,000 in shares of U.S. Bancorp NYSE: USB on 3/10/2025.
- Purchased $1,001 - $15,000 in shares of CME Group NASDAQ: CME on 3/10/2025.
- Sold $1,001 - $15,000 in shares of Target NYSE: TGT on 3/10/2025.
- Purchased $1,001 - $15,000 in shares of American Water Works NYSE: AWK on 3/10/2025.
Gilead Sciences Price Performance
Shares of Gilead Sciences stock traded down $0.39 during midday trading on Friday, reaching $104.49. The company had a trading volume of 8,066,368 shares, compared to its average volume of 7,519,796. The stock has a fifty day simple moving average of $109.16 and a 200 day simple moving average of $97.45. Gilead Sciences, Inc. has a 1-year low of $62.07 and a 1-year high of $119.96. The company has a current ratio of 1.50, a quick ratio of 1.20 and a debt-to-equity ratio of 1.24. The company has a market capitalization of $130.10 billion, a price-to-earnings ratio of 282.40, a price-to-earnings-growth ratio of 0.71 and a beta of 0.32.
Gilead Sciences (NASDAQ:GILD - Get Free Report) last released its earnings results on Tuesday, February 11th. The biopharmaceutical company reported $1.90 earnings per share for the quarter, topping analysts' consensus estimates of $1.67 by $0.23. Gilead Sciences had a return on equity of 31.63% and a net margin of 1.67%. As a group, equities research analysts forecast that Gilead Sciences, Inc. will post 7.95 earnings per share for the current year.
Gilead Sciences Increases Dividend
The business also recently announced a quarterly dividend, which was paid on Friday, March 28th. Stockholders of record on Friday, March 14th were given a dividend of $0.79 per share. This represents a $3.16 dividend on an annualized basis and a dividend yield of 3.02%. This is a positive change from Gilead Sciences's previous quarterly dividend of $0.77. The ex-dividend date of this dividend was Friday, March 14th. Gilead Sciences's dividend payout ratio is presently 854.05%.
Analyst Ratings Changes
GILD has been the subject of a number of analyst reports. Wells Fargo & Company lifted their target price on shares of Gilead Sciences from $120.00 to $140.00 and gave the stock an "overweight" rating in a report on Wednesday, March 5th. Royal Bank of Canada raised their target price on Gilead Sciences from $84.00 to $90.00 and gave the stock a "sector perform" rating in a report on Wednesday, February 12th. The Goldman Sachs Group lifted their price objective on shares of Gilead Sciences from $85.00 to $96.00 and gave the stock a "neutral" rating in a research note on Wednesday, February 12th. Oppenheimer increased their target price on shares of Gilead Sciences from $115.00 to $132.00 and gave the stock an "outperform" rating in a report on Tuesday, March 4th. Finally, DZ Bank upgraded shares of Gilead Sciences from a "hold" rating to a "buy" rating and set a $108.00 price objective for the company in a research report on Thursday, February 13th. Eleven analysts have rated the stock with a hold rating, fifteen have given a buy rating and four have assigned a strong buy rating to the company. According to data from MarketBeat, the stock has a consensus rating of "Moderate Buy" and a consensus target price of $105.12.
Read Our Latest Stock Analysis on GILD
Insider Transactions at Gilead Sciences
In other news, CFO Andrew D. Dickinson sold 2,500 shares of Gilead Sciences stock in a transaction that occurred on Tuesday, April 15th. The shares were sold at an average price of $106.40, for a total value of $266,000.00. Following the completion of the sale, the chief financial officer now directly owns 168,174 shares in the company, valued at approximately $17,893,713.60. The trade was a 1.46 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. Over the last 90 days, insiders sold 302,785 shares of company stock valued at $30,540,875. 0.27% of the stock is currently owned by corporate insiders.
Institutional Trading of Gilead Sciences
Hedge funds have recently modified their holdings of the stock. Redwood Financial Network Corp boosted its holdings in shares of Gilead Sciences by 4.0% during the fourth quarter. Redwood Financial Network Corp now owns 2,530 shares of the biopharmaceutical company's stock worth $234,000 after acquiring an additional 98 shares during the period. Nicolet Advisory Services LLC boosted its stake in Gilead Sciences by 2.9% in the 4th quarter. Nicolet Advisory Services LLC now owns 3,580 shares of the biopharmaceutical company's stock valued at $322,000 after purchasing an additional 100 shares during the period. Peak Financial Advisors LLC boosted its stake in Gilead Sciences by 1.7% in the 1st quarter. Peak Financial Advisors LLC now owns 6,040 shares of the biopharmaceutical company's stock valued at $677,000 after purchasing an additional 100 shares during the period. Perkins Coie Trust Co grew its holdings in Gilead Sciences by 2.6% in the 1st quarter. Perkins Coie Trust Co now owns 3,880 shares of the biopharmaceutical company's stock valued at $435,000 after buying an additional 100 shares in the last quarter. Finally, Southland Equity Partners LLC increased its position in Gilead Sciences by 3.6% during the 4th quarter. Southland Equity Partners LLC now owns 3,128 shares of the biopharmaceutical company's stock worth $289,000 after buying an additional 110 shares during the period. Institutional investors and hedge funds own 83.67% of the company's stock.
About Representative Miller
Carol Miller (Republican Party) is a member of the U.S. House, representing West Virginia's 1st Congressional District. She assumed office on January 3, 2023. Her current term ends on January 3, 2027.
Miller (Republican Party) ran for re-election to the U.S. House to represent West Virginia's 1st Congressional District. She won in the general election on November 5, 2024.
West Virginia's 3rd Congressional District race was identified as a 2018 battleground that might have affected partisan control of the U.S. House in the 116th Congress. Incumbent Evan Jenkins (R) did not seek re-election in 2018, leaving the seat open. In the campaign, Miller emphasized her endorsement by President Donald Trump (R). Lara Trump, Senior Advisor to Donald J. Trump for President, Inc., said, "Carol is pro-coal, pro-Second Amendment, and pro-Trump through and through, and is prepared to tackle the opioid epidemic that’s affected countless West Virginians." Miller also supported the construction of a wall on the southern U.S. border and the Tax Cuts and Jobs Act (TCJA).
Miller is a former Republican member of the West Virginia House of Delegates, representing District 16 from 2006 to 2018.
Miller has also worked in real estate and owns a bison farm.
Carol Miller was born in Columbus, Ohio. Miller graduated from Bexley High School in 1968. She earned a B.S. from Columbia College in 1972. Her career experience includes owning and operating Swann Ridge Bison Farm and working as a real estate manager.
About Gilead Sciences
(
Get Free Report)
Gilead Sciences, Inc, a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, Sunlencs, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of COVID-19; and Epclusa, Harvoni, Vemlidy, and Viread for the treatment of viral hepatitis.
Featured Articles
Before you consider Gilead Sciences, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Gilead Sciences wasn't on the list.
While Gilead Sciences currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
MarketBeat's analysts have just released their top five short plays for June 2025. Learn which stocks have the most short interest and how to trade them. Enter your email address to see which companies made the list.
Get This Free Report
